Literature DB >> 8845831

Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo.

T Oikawa1, C Onozawa, M Inose, M Sasaki.   

Abstract

Depudecin, a microbial metabolite containing two epoxide groups, was tested for its anti-angiogenic activity in an in vivo assay system involving the chorioallantoic membrane of growing chick embryo. The microbial metabolite inhibited embryonic angiogenesis in a dose-dependent manner with an ID50 of 320 ng (1.5 nmol) per egg. It also affected the growth of vascular endothelial cells, a key event in the process of angiogenesis in vivo. These results suggest that depudecin could be promising as an anti-angiogenic agent and that its anti-angiogenic action involves an inhibitory effect on vascular endothelial cell growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8845831     DOI: 10.1248/bpb.18.1305

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  4 in total

Review 1.  An overview of naturally occurring histone deacetylase inhibitors.

Authors:  Bumki Kim; Jiyong Hong
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

2.  Effects of endostatin and a new drug terpestacin against human neuroblastoma xenograft and cell lines.

Authors:  Ki Cheong Park; Seung Hoon Choi
Journal:  Pediatr Surg Int       Date:  2013-12       Impact factor: 1.827

3.  Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase.

Authors:  H J Kwon; T Owa; C A Hassig; J Shimada; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

4.  Inhibition of angiogenesis by rhizoxin, a microbial metabolite containing two epoxide groups.

Authors:  C Onozawa; M Shimamura; S Iwasaki; T Oikawa
Journal:  Jpn J Cancer Res       Date:  1997-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.